Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Caremark Reaps Pricing Benefit From AdvancePCS Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

The PBM is looking for additional mergers and acquisitions outside pharmacy benefit management.

You may also be interested in...

Statin Prices Likely To Remain High After Zocor Exclusivity Win

Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.

Teva Launches Generic Pravachol Following Appeals Court Dismissal Of Apotex

Watson concurrently launched an authorized generic of Bristol's pravastatin, but Ranbaxy's 80 mg ANDA remains on hold.

Caremark To Implement New Business Practices Under Settlement With U.S. Attorney

The $137.5 mil. settlement requires Caremark to inform client plans of rebates earned as a percentage of the PBM’s total product revenue.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts